Patents by Inventor Marina Veronesi

Marina Veronesi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9949968
    Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses as anti-proliferative and proapoptotic agents for cancer therapy.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: April 24, 2018
    Assignee: Fondazione Istituto Italiano Di Tecnologia
    Inventors: Benedetto Grimaldi, Esther Torrente, Rita Scarpelli, Giovanni Bottegoni, Tiziano Bandiera, Marina Veronesi
  • Publication number: 20170136009
    Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses as anti-proliferative and proapoptotic agents for cancer therapy.
    Type: Application
    Filed: November 22, 2016
    Publication date: May 18, 2017
    Inventors: Benedetto Grimaldi, Esther Torrente, Rita Scarpelli, Giovanni Bottegoni, Tiziano Bandiera, Marina Veronesi
  • Patent number: 9611245
    Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses as anti-proliferative and pro-apoptotic agents for cancer therapy.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: April 4, 2017
    Assignee: Fondazione Istituto Italiano Di Tecnologia
    Inventors: Benedetto Grimaldi, Esther Torrente, Rita Scarpelli, Giovanni Bottegoni, Tiziano Bandiera, Marina Veronesi
  • Publication number: 20160237057
    Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses as anti-proliferative and pro-apoptotic agents for cancer therapy.
    Type: Application
    Filed: October 9, 2014
    Publication date: August 18, 2016
    Inventors: Benedetto Grimaldi, Esther Torrente, Rita Scarpelli, Giovanni Bottegoni, Tiziano Bandiera, Marina Veronesi
  • Publication number: 20080233603
    Abstract: High-Throughput Screening (HTS) of large compound libraries is the method of drug-lead discovery. It is now well accepted that for a functional assay, quality is more important than quantity. A biochemical NMR method originally proposed by Percival and Withers (Biochemistry, 1992, 31, 498-505) is extended to the screening of Ser/Thr kinases. The method requires the presence of a CF3 (or CF) moiety on the substrate and utilizes 19F NMR spectroscopy for the detection of the starting and enzymatically modified substrates. Experiments can be performed in real time or in an endpoint assay format using protein and substrate concentrations comparable to the ones used by other HTS techniques. Application of this technique to the phosphorylation of a substrate by the protein Ser/Thr kinase AKT1 is presented.
    Type: Application
    Filed: July 9, 2007
    Publication date: September 25, 2008
    Applicant: Pfizer Italia S.r.l.
    Inventors: Claudio Dalvit, Elena Ardini, Maria Magdalena Flocco, Gianpaolo Fogliatto, Nicola Mongelli, Marina Veronesi
  • Patent number: 7255985
    Abstract: High-Throughput Screening (HTS) of large compound libraries is the method of drug-lead discovery. It is now well accepted that for a functional assay, quality is more important than quantity. A biochemical NMR method originally proposed by Percival and Withers (Biochemistry, 1992, 31, 498–505) is extended to the screening of Ser/Thr kinases. The method requires the presence of a CF3 (or CF) moiety on the substrate and utilizes 19F NMR spectroscopy for the detection of the starting and enzymatically modified substrates. Experiments can be performed in real time or in an endpoint assay format using protein and substrate concentrations comparable to the ones used by other HTS techniques. Application of this technique to the phosphorylation of a substrate by the protein Ser/Thr kinase AKT1 is presented.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: August 14, 2007
    Assignee: Pfizer Italia S.r.l.
    Inventors: Claudio Dalvit, Elena Ardini, Maria Magdalena Flocco, Gianpaolo Fogliatto, Nicola Mongelli, Marina Veronesi
  • Publication number: 20050048594
    Abstract: High-Throughput Screening (HTS) of large compound libraries is the method of drug-lead discovery. It is now well accepted that for a functional assay, quality is more important than quantity. A biochemical NMR method originally proposed by Percival and Withers (Biochemistry, 1992, 31, 498-505) is extended to the screening of Ser/Thr kinases. The method requires the presence of a CF3 (or CF) moiety on the substrate and utilizes 19F NMR spectroscopy for the detection of the starting and enzymatically modified substrates. Experiments can be performed in real time or in an endpoint assay format using protein and substrate concentrations comparable to the ones used by other HTS techniques. Application of this technique to the phosphorylation of a substrate by the protein Ser/Thr kinase AKT1 is presented.
    Type: Application
    Filed: July 9, 2004
    Publication date: March 3, 2005
    Applicant: Pharmacia Italia S.p.A.
    Inventors: Claudio Dalvit, Elena Ardini, Maria Flocco, Gianpaolo Fogliato, Nicola Mongelli, Marina Veronesi
  • Publication number: 20040091937
    Abstract: High-Throughput ligand-based NMR screening with competition binding experiments using 19F detection.
    Type: Application
    Filed: June 5, 2003
    Publication date: May 13, 2004
    Inventors: Claudio Dalvit, Brian J. Stockman, Maria Flocco, Marina Veronesi